iec62304
(2)
Angio8
Angio8 (Shenzhen Tonglu Technology, 通甪科技) is a medical robotics company building a surgical robot and treatment platform for minimally invasive vascular interventional procedures. Its system lets physicians remotely manipulate catheters and guidewires with force feedback, aiming to make interventional surgery safer, more precise, and less reliant on repeated radiation exposure for the operating team. Founded in 2021 and based in Shenzhen's Bao'an District, the company is led by co-founder and CEO Yunfei (Richard) Cao and is backed by investors including Oriental Fortune Capital, Kangyu Capital and Ruiqian Capital.
Yunfei Cao
Yunfei 'Richard' Cao is the co-founder and CEO of Angio8 (通甪科技), a Shenzhen-based startup building a next-generation surgical robot for minimally invasive vascular interventional surgery. A Stony Brook biomedical engineer who cut his teeth inside the Boston medical-device machine at Vention Medical, SunMed and China Med Device, Cao now runs a cross-Pacific company - engineering brains in Boston, manufacturing and clinical work in Shenzhen - aimed at letting doctors steer catheters and guidewires by robot instead of by hand.